NPT-133

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameNPT-133
Drug Alias Namesecond generation therapeutics (NeuroPhage Pharmaceuticals)NPT-133NPT-289
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionBeta amyloid A4 protein aggregation inhibitorsFc receptors agonistsSynuclein alpha inhibitors +[5] 
TargetsMicrotubule-associated protein tauBeta amyloid A4 proteinFc receptors +[4] 
Therapy Area/IndicationsNerve DegenerationAmyloidosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesProclara Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesProclara Biosciences Inc
Active IndicationsN/A
Inactive IndicationsNerve DegenerationAmyloidosis

Other Information

ATC CodeN/A
Related LinksN/A